Classification of current anticancer immunotherapies

Galluzzi, Lorenzo, Vacchelli, Erika, Bravo-San Pedro, Jose-Manuel, Buque, Aitziber, Senovilla, Laura, Baracco, Elisa Elena, Bloy, Norma, Castoldi, Francesca, Abastado, Jean-Pierre, Agostinis, Patrizia, Apte, Ron N., Aranda, Fernando, Ayyoub, Maha, Beckhove, Philipp, Blay, Jean-Yves, Bracci, Laura, Caignard, Anne, Castelli, Chiara, Cavallo, Federica, Celis, Estaban, Cerundolo, Vincenzo, Clayton, Aled, Colombo, Mario P., Coussens, Lisa, Dhodapkar, Madhav V., Eggermont, Alexander M., Fearon, Douglas T., Fridman, Wolf H., Fucikova, Jitka, Gabrilovich, Dmitry I., Galon, Jerome, Garg, Abhishek, Ghiringhelli, Francois, Giaccone, Giuseppe, Gilboa, Eli, Gnjatic, Sacha, Hoos, Axel, Hosmalin, Anne, Jaeger, Dirk, Kalinski, Pawel, Kaerre, Klas, Kepp, Oliver, Kiessling, Rolf, Kirkwood, John M., Klein, Eva, Knuth, Alexander, Lewis, Claire E., Liblau, Roland, Lotze, Michael T., Lugli, Enrico, Mach, Jean-Pierre, Mattei, Fabrizio, Mavilio, Domenico, Melero, Ignacio, Melief, Cornelis J., Mittendorf, Elizabeth A., Moretta, Lorenzo, Odunsi, Adekunke, Okada, Hideho, Palucka, Anna Karolina, Peter, Marcus E., Pienta, Kenneth J., Porgador, Angel, Prendergast, George C., Rabinovich, Gabriel A., Restifo, Nicholas P., Rizvi, Naiyer, Sautes-Fridman, Catherine, Schreiber, Hans, Seliger, Barbara, Shiku, Hiroshi, Silva-Santos, Bruno, Smyth, Mark J., Speiser, Daniel E., Spisek, Radek, Srivastava, Pramod K., Talmadge, James E., Tartour, Eric, Van der Burg, Sjoerd H., Van den Eynde, Benoit J., Vile, Richard, Wagner, Hermann, Weber, Jeffrey S., Whiteside, Theresa L., Wolchok, Jedd D., Zitvogel, Laurence, Zou, Weiping and Kroemer, Guido (2014) Classification of current anticancer immunotherapies. Oncotarget, 5 24: 12472-12508. doi:10.18632/oncotarget.2998

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Galluzzi, Lorenzo
Vacchelli, Erika
Bravo-San Pedro, Jose-Manuel
Buque, Aitziber
Senovilla, Laura
Baracco, Elisa Elena
Bloy, Norma
Castoldi, Francesca
Abastado, Jean-Pierre
Agostinis, Patrizia
Apte, Ron N.
Aranda, Fernando
Ayyoub, Maha
Beckhove, Philipp
Blay, Jean-Yves
Bracci, Laura
Caignard, Anne
Castelli, Chiara
Cavallo, Federica
Celis, Estaban
Cerundolo, Vincenzo
Clayton, Aled
Colombo, Mario P.
Coussens, Lisa
Dhodapkar, Madhav V.
Eggermont, Alexander M.
Fearon, Douglas T.
Fridman, Wolf H.
Fucikova, Jitka
Gabrilovich, Dmitry I.
Galon, Jerome
Garg, Abhishek
Ghiringhelli, Francois
Giaccone, Giuseppe
Gilboa, Eli
Gnjatic, Sacha
Hoos, Axel
Hosmalin, Anne
Jaeger, Dirk
Kalinski, Pawel
Kaerre, Klas
Kepp, Oliver
Kiessling, Rolf
Kirkwood, John M.
Klein, Eva
Knuth, Alexander
Lewis, Claire E.
Liblau, Roland
Lotze, Michael T.
Lugli, Enrico
Mach, Jean-Pierre
Mattei, Fabrizio
Mavilio, Domenico
Melero, Ignacio
Melief, Cornelis J.
Mittendorf, Elizabeth A.
Moretta, Lorenzo
Odunsi, Adekunke
Okada, Hideho
Palucka, Anna Karolina
Peter, Marcus E.
Pienta, Kenneth J.
Porgador, Angel
Prendergast, George C.
Rabinovich, Gabriel A.
Restifo, Nicholas P.
Rizvi, Naiyer
Sautes-Fridman, Catherine
Schreiber, Hans
Seliger, Barbara
Shiku, Hiroshi
Silva-Santos, Bruno
Smyth, Mark J.
Speiser, Daniel E.
Spisek, Radek
Srivastava, Pramod K.
Talmadge, James E.
Tartour, Eric
Van der Burg, Sjoerd H.
Van den Eynde, Benoit J.
Vile, Richard
Wagner, Hermann
Weber, Jeffrey S.
Whiteside, Theresa L.
Wolchok, Jedd D.
Zitvogel, Laurence
Zou, Weiping
Kroemer, Guido
Title Classification of current anticancer immunotherapies
Journal name Oncotarget   Check publisher's open access policy
ISSN 1949-2553
Publication date 2014-12-01
Year available 2014
Sub-type Critical review of research, literature review, critical commentary
DOI 10.18632/oncotarget.2998
Open Access Status File (Publisher version)
Volume 5
Issue 24
Start page 12472
End page 12508
Total pages 37
Place of publication Albany, NY United States
Publisher Impact Journals
Language eng
Subject 2730 Oncology
Abstract During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into “passive” and “active” based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.
Keyword Adoptive cell transfer
Checkpoint blockers
Dendritic cell-based interventions
DNA-based vaccines
Immunostimulatory cytokines
Peptide-based vaccines
Oncolytic viruses
Toll-like receptor agonists
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2015 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 129 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 139 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 22 Mar 2015, 11:39:30 EST by System User on behalf of School of Medicine